Sarepta Therapeutics

Sarepta Therapeutics (Cambridge, MA). 2024 revenue ~$1.9B. Duchenne muscular dystrophy: Elevidys (delandistrogene moxeparvovec, gene therapy), Amondys 45, Vyondys 53. PMO phosphorodiamidate morpholino oligomers.